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Abstract
Background: Over the past two decades more than fifty thousand unique clinical and biological samples have
been assayed using the Affymetrix HG-U133 and HG-U95 GeneChip microarray platforms. This substantial repository
has been used extensively to characterize changes in gene expression between biological samples, but has not
been previously mined en masse for changes in mRNA processing. We explored the possibility of using HG-U133
microarray data to identify changes in alternative mRNA processing in several available archival datasets.
Results: Data from these and other gene expression microarrays can now be mined for changes in transcript
isoform abundance using a program described here, SplicerAV. Using in vivo and in vitro breast cancer microarray
datasets, SplicerAV was able to perform both gene and isoform specific expression profiling within the same
microarray dataset. Our reanalysis of Affymetrix U133 plus 2.0 data generated by in vitro over-expression of HRAS,
E2F3, beta-catenin (CTNNB1), SRC, and MYC identified several hundred oncogene-induced mRNA isoform changes,
one of which recognized a previously unknown mechanism of EGFR family activation. Using clinical data, SplicerAV
predicted 241 isoform changes between low and high grade breast tumors; with changes enriched among genes
coding for guanyl-nucleotide exchange factors, metalloprotease inhibitors, and mRNA processing factors. Isoform
changes in 15 genes were associated with aggressive cancer across the three breast cancer datasets.
Conclusions: Using SplicerAV, we identified several hundred previously uncharacterized isoform changes induced
by in vitro oncogene over-expression and revealed a previously unknown mechanism of EGFR activation in human
mammary epithelial cells. We analyzed Affymetrix GeneChip data from over 400 human breast tumors in three
independent studies, making this the largest clinical dataset analyzed for en masse changes in alternative mRNA
processing. The capacity to detect RNA isoform changes in archival microarray data using SplicerAV allowed us to
carry out the first analysis of isoform specific mRNA changes directly associated with cancer survival.
Background
The key postulate that one gene encodes one polypep-
tide chain (one enzyme) has been overhauled with the
discovery that one gene can generate multiple RNA
transcripts (and indirectly many different polypeptide
chains) through a process referred to as alternative
mRNA processing [1]. Alternative processing defines a
range of events, including alternative splicing and alter-
native polyadenylation, which result in distinct mRNA
species. Recent deep sequencing studies indicate that
94% of all protein coding genes generate multiple
mRNA transcripts [2] and mutations affecting mRNA
splicing are responsible for an estimated 15-60% of
human genetic diseases [3,4]. Functional consequences
of alternative processing have been shown across a wide
variety of biological processes (reviewed by [5-7])
including drug metabolism, stem cell renewal, neurolo-
gic disease, autoimmune disease, and especially cancer.
Despite the importance of alternative processing in can-
cer, current understanding of its global regulation
remains sparse [8] and limits the ability to fully harness
alternative processing as a tool in cancer prognosis,
diagnosis, and treatment.
Attempts to obtain a genome scale understanding of
alternative processing in cancer have focused on large-
scale characterizations of changes in alternative proces-
sing between normal tissue and cancer. Bioinformatic
analyses have identified a large number of transcript iso-
forms found only within cancer tissue [9-11]. The recent
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fication of changes in alternative processing between
individual samples (reviewed in [1]). These arrays have
been used to detect changes in alternative processing
between normal human tissues and in breast, brain,
colon, prostate, and bladder carcinomas [12-16] using
various splicing algorithms (reviewed in [17]). Large
scale clinical analyses of changes in alternative proces-
sing; however, remain sparse, and there are no high-
throughput analyses of changes in mRNA processing
associated with poor patient prognosis. Such studies
require years of patient follow-up and have not been
reported using the new splicing arrays.
In contrast, public repositories such as the Gene
Expression Omnibus (GEO) currently contain conven-
tional gene expression data from hundreds of thousands
of unique biological or clinical samples ([18]). Data pre-
viously generated by the microarray community provide
an untapped source of potential insight to the regulation
of alternative mRNA processing in human cancer.
Although the exact value of these data is not known, it
is likely that well over a billion dollars have been
invested in reagents, facility, and personnel costs over
the past two decades.
The first commercially available high-density gene
expression microarrays were invented three decades ago
by Affymetrix [19] to quantify expression changes in
tens of thousands of genes in a single experiment, but
w e r en o ti n t e n d e dt od e t e c ti s o f o r ms p e c i f i cm R N A
changes resulting from alternative processing. Two of
the most commonly used human expression microar-
rays, the Affymetrix U95 and U133 series, use individual
probesets to report expression of many genes. Each pro-
beset is composed of 11 individual 25 nt oligomers that
interrogate a subsequence of the target gene. Both plat-
forms, however, contain thousands of genes whose
expression is assayed by more than one probeset. The
use of multiple probesets, which often interrogate non-
overlapping regions of the target gene, was originally
intended to provide a robust assay of gene expression.
We and others have previously observed that discrepan-
cies between fold-changes in probesets interrogating the
same gene can represent isoform-specific changes in
mRNA levels [20-22]. Such isoform changes can result
from alternative transcription start sites, alternative
mRNA processing, or changes in mRNA isoform
stability.
Methods that detect isoform-specific mRNA changes
have been developed for splicing microarrays such as
the Affymetrix Human Exon 1.0 ST (reviewed in [17]),
but have not been developed for or applied to conven-
tional gene expression microarrays. In fact, it has been
suggested in such reviews that “detection of disease-rele-
vant splicing differences may be entirely missed in gene-
level expression profiling studies” [17]. Although it may
be possible in theory to apply such methods to conven-
tional gene expression microarrays, to our knowledge
this has not been done. To fully investigate the potential
to detect isoform-specific mRNA changes in conven-
tional gene expression microarray data, we elected to
develop a novel method, SplicerAV, which we have
applied to conventional Affymetrix gene expression
microarray data.
For the Affymetrix GeneChip Human U133 plus 2.0
arrays, 11,193 genes, which represent 57% of uniquely
annotated genes assayed by the array, are interrogated
by multiple probesets and can therefore be queried for
mRNA isoform changes, with an average of 3.2 probe-
sets interrogating these genes (Table 1). For the U133A
a r r a y s ,3 6 %a r ei n t e r r o g a t e db ym u l t i p l ep r o b e s e t s ,w i t h
an average of 2.7 probesets per gene for a total of 4,609
g e n e s .T h eU 1 3 3s e r i e so fa r r a yp l a t f o r m sa r ea m o n g
the most commonly used platforms within GEO (over
40,000 samples) and have the potential to detect isoform
changes in thousands of genes.
SplicerAV is a program created to systematically
assess the likelihood of changes in alternative processing
evidenced by discrepancies in probeset behavior using a
Gaussian mixture model of mRNA transcript regulation.
A beta version of this program, which lacked biological
modifiers and the ability to generate estimates of statis-
tical significance, was initially used to identify differen-
tial regulation of transcript isoforms by TCERG1 [20].
SplicerAV can be applied to any expression microarray
platform with multiple probesets interrogating the same
gene, without the need for detailed transcript annota-
tion. The program provides a non-computationally
intensive algorithm capable of analyzing probeset-sum-
mary level datasets for evidence of changes in alternative
mRNA processing. We provide here a description of
SplicerAV, which has been developed to provide a rigor-
ous statistical model and incorporate biologically moti-
vated modifications with the goal of assisting biologists
in identifying alternative processing events most amen-
able for in-depth study from conventional gene expres-
sion microarray data.
In this study SplicerAV’su n i q u ev a l u ei nd e t e c t i n g
previously overlooked changes in mRNA processing is
demonstrated using publicly available Affymetrix U133
gene expression datasets. SplicerAV was used to uncover
previously uncharacterized isoform specific changes in
epidermal growth factor receptor (EGFR)c a u s e db yin
vitro HRAS over-expression [23]. In a separate analysis,
SplicerAV was used to identify changes in alternative
mRNA processing associated with poor patient prog-
nosis in over 400 breast tumors. Here we demonstrate
SplicerAV’s ability to examine archival data, performing
the largest analysis of alternative mRNA processing in
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analysis of changes in alternative mRNA processing
associated with human cancer prognosis.
Results and Discussion
SplicerAV Algorithm
There are two main steps in the SplicerAV analysis. The
first step summarizes individual probeset changes in
expression between a user defined group of control and
treatment observations. The second step evaluates these
probeset level summaries for evidence of changes in
alternative processing using a Gaussian mixture model
(Figure 1).
In the first step, changes in probeset expression levels
are summarized by calculating their average log2fold
changes and corresponding t-statistics. These metrics
were taken from conventional gene expression analysis.
Probesets targeting the same gene are then grouped
together and each probeset is assigned a weight. Indivi-
dual probeset weights are calculated using a combina-
tion of that probeset’s t-statistic, number of
observations, and comparison with other probesets tar-
geting the same gene (see methods).
Once these weights are assigned, each gene is evalu-
ated for evidence of alternative processing using a Gaus-
sian mixture model. In the Gaussian mixture model
used by SplicerAV, probesets interrogating a transcrip-
tionally activated gene are predicted to detect the same
proportional increase in expression. For example, probe-
sets targeting an mRNA that doubles in abundance
w o u l db ee x p e c t e dt od o u b l ei ni n t e n s i t y( F i g u r e1 B ) .
Conversely, probesets targeting an mRNA which is
down-regulated by half would be expected to be reduced
by half Figure 1C). Multiple probesets targeting a gene
that is alternatively processed or undergoes isoform spe-
cific mRNA regulation would be expected to report dis-
cordant changes in probeset intensities (Figure 1D).
Plotting the same aforementioned hypothetical data as
log2 fold-changes emphasizes that in alternatively pro-
cessed mRNAs, summarized probeset behavior clusters
into discrete groups (Figure 1, right). SplicerAV assesses
this grouping mathematically assuming a Gaussian mix-
ture model, which compares fitting the data using one
vs. two Gaussian distributions. Fitting the probeset
expression data with a single Gaussian curve equates to
a biological model in which the gene is regulated as one
expression unit (e.g., all transcripts are destabilized
equally). Fitting the data with a two Gaussian model
equates to a biological model in which the gene is regu-
lated as two or more expression units, corresponding to
changes in isoform specific regulation. Comparing the
ratio of how well each model fits the summarized pro-
beset data gives a maximum likelihood ratio, or MLR,
which gives an indication of how well the summarized
Table 1 SplicerAV related probeset features of commonly used Affymetrix microarrays
Platform Unique Annotated
Genes
Genes w/Mult
Probesets
Fraction of genes w/mult
probesets
Avg. Probesets per
gene
Unannotated
Probesets
Total
Probesets
U133 Plus 2.0 19,761 11,193 57% 3.2 9818 54,675
U133 A 12,737 4,609 36% 2.7 1917 22,283
U95 A 8,690 1,946 22% 2.4 1253 12,651
Mouse 430A 2 12,755 4,934 39% 2.6 2118 22,690
Figure 1 Gaussian mixture model of changes in alternative
processing. Absolute expression of a hypothetical gene is reported
by four independent probesets targeting different regions of this
gene; I, II, III, IV (left panels) for control and treatment conditions
(open and closed bars respectively). The idealized Gaussian mixture
models representing changes in probeset behavior are illustrated in
the right panels. Panels A, B, and C represent concordant probeset
behaviors corresponding to no change, an increase, and a decrease,
respectively. Panel D represents discordant behavior; two probesets
(I, II) report an increase, while the remaining probesets (III, IV) report
a decrease in expression between conditions (control and
treatment). Probesets may report discrepant changes in gene
expression depending on which region of the mRNA transcript they
interrogate.
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processing relative to whole transcript regulation. The
lowest possible log MLR for a gene is zero, which indi-
cates that all probesets change proportionally and sug-
gests no evidence of alternative processing. Log MLRs
greater than zero indicate discrepancy in the expression
changes in the probesets, which can be caused by an
alternative processing event. The greater the value of
the log MLR the more likely a gene is to be alternatively
processed (see methods for more details).
MLR
Likelihood of probeset data Two Gaussian Curves
Likelihood
= () |
o of probeset data Single Gaussian Curve | ()
(1)
SplicerAV uses the chip annotation file ("platform_an-
not.csv” for Affymetrix arrays) to determine which pro-
besets interrogate the same gene. For most microarray
platforms the gene symbol provides an appropriate
annotation scheme, however any provided annotation
(Transcript cluster ID, WormBase, FlyBase, Ensembl,
etc.) can be used.
Probeset Annotation & Filtering
Our analyses used the default probeset annotation pro-
vided by Affymetrix. This annotation contains probesets
that in some cases target multiple exons or are poorly
annotated [24-26]. Re-defining probeset definition, for
example using exon-based definitions of probesets, may
improve the ability of SplicerAV to detect changes in
mRNA processing [24,25]. However, using the standard
annotation provided by Affymetrix makes our findings
here directly comparable to the vast majority of expres-
sion analyses conducted using the U133 series of arrays,
allowing reference to specific probeset IDs and enabling
us to directly analyze summarized expression datasets
deposited in GEO. Additionally, many Affymetrix micro-
array expression datasets deposited in GEO do not con-
tain CEL files [26] and cannot be re-analyzed using
custom annotation.
The use of standard Affymetrix annotation also allows
us to make presence/absence probeset detection calls
using previously validated methods [27]. As described
above, SplicerAV detects discrepancies in fold changes
between probesets targeting the same gene, using these
discrepancies to infer changes in alternative mRNA pro-
cessing. Nevertheless, such discrepancies can also reflect
the presence of negative strand matching probesets
(NSMPs) or probesets that do not produce signal above
background, which can be caused by low transcript
levels or non-functional probes. NSMPs hybridize or
detect RNAs transcribed in the opposite direction of the
annotated gene; they do not reflect the expression of
the target transcript and are identified and removed by
SplicerAV using information available in standard
Affymetrix annotation files [27]. Probesets that do not
produce signal can also falsely suggest isoform specific
mRNA changes. These probesets are removed by Spli-
cerAV if they are not expressed above background (P <
.05) in either treatment or control groups using the Pre-
sence-Absence calls with Negative Probesets (PANP)
algorithm [27].
Biological Modifiers
The original motivation for SplicerAV was to identify
statistically significant changes in alternative processing
that would also provide ideal targets for further experi-
mental validation and study. To this end, we incorpo-
rated additional, user-modifiable parameters, which can
preferentially rank events expected to be more amenable
to experimental investigation. There are three biological
modifiers applied to the MLR to generate the final splice
score: a multiple probeset correction to adjust for total
possible paired groupings of probesets, an expression
cutoff modifier to specify the minimum change required
between isoforms, and a centering modifier to preferen-
tially rank genes whose probeset expression levels
change in opposite directions. All modifiers are normal-
ized by the average number of paired control and treat-
ment observations for all probesets within a gene
(Avg_Obs), so that large samples with higher statistical
power will be as influenced by the modifiers as smaller
samples, providing parameters that can be applied with
consistent effects across varying sample sizes (see equa-
tion 2 and methods).
Splice Score MLR Avg Obs
Multiple probeset Cutoff Centering
=+
++
_
*( M Modifiers)
(2)
These modifiers do not affect the p-value generated by
SplicerAV, but allow the program to preferentially rank
predicted changes in alternative processing that generate
less complicated hypotheses, are larger in magnitude,
reflect changes in expression which are qualitatively dif-
ferent, and are less likely to reflect probesets targeting
non-transcribed regions or probesets that do not linearly
reflect changes in transcript abundance. Genes that
exhibit statistically significant discordant probeset beha-
vior and are given a positive splice score represent ideal
candidates for experimental investigation of isoform spe-
cific regulation.
SplicerAV generates several additional outputs with
each file. These include a file containing assessment of
statistically significant expression changes for all probe-
sets, a log file containing all user set parameters and
comparisons made, as well as a FASTA file for each
gene. These fasta files contain the target sequences of
all probesets targeting that gene, allowing quick and
easy mapping to known and predicted mRNA sequences
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edu[28]. All genomic analyses in this study were per-
formed using the March 2006 release of the human gen-
ome (hg18).
SplicerAV Index Generation
To perform analyses of isoform changes within indivi-
dual samples we derived an index of relative isoform
abundance predicted by SplicerAV. High-throughput
analyses of alternative processing have previously
defined “splice index” as a quantitative measure to com-
pare isoform abundances between individual samples.
The splice index of a probeset equals its expression rela-
tive to other probesets targeting the same gene [29].
Using SplicerAV we defined a modified version of the
splice index, referred to as the SplicerAV index. Spli-
cerAV assumes a Gaussian mixture model, whereby all
probesets are classified as belonging to one of two
groups based on similarity of expression changes. The
group of probesets exhibiting the largest increases in
expression are referred to as the “A” (up) group and the
group of probesets exhibiting the largest decreases in
expression are referred to as the “B” (down) group (see
examples of SplicerAV output in additional files 1, 2, 3,
4, 5, and 6). The SplicerAV index of a probeset equals
its expression relative to the average expression of pro-
besets in the opposite group. For example, the Spli-
cerAV index of a probeset in the “A” group would be
calculated by subtracting the average expression of the
“B” group from that probeset’s log2 expression value. In
our analysis, SplicerAV indexes of probesets in the “A”
group were defined as increased in aggressive cancers,
while indexes of probesets in the “B” group were defined
as decreased in aggressive cancers. Pre-specified hypoth-
eses generated in training datasets made unidirectional
significance tests appropriate in independent validation
datasets.
SplicerAV Implementation
SplicerAV was implemented in Perl, with a typical run
time of 3-5 minutes on a standard personal computer
and has not been tested using other operating systems.
The program will only assess changes in alternative
mRNA processing for genes interrogated by multiple
probesets, which varies widely by microarray platform.
To explore the potential for SplicerAV to identify novel
changes in mRNA isform abundance in breast cancer,
we applied SplicerAV to several publicly available, archi-
val Affymetrix HG-U133 plus 2.0 datasets.
SplicerAV predicts oncogene induced changes in
alternative processing of splicing factors
Studies of SRC [30], HRAS [31,32], and E2F family bind-
ing sites [33] have demonstrated isolated roles of these
oncogenes in affecting alternative mRNA processing.
Nonetheless, prior to this study no large-scale examina-
tion of changes in alternative mRNA processing had
been undertaken for any of these oncogenes. We exam-
ined an oncogene over-expression microarray dataset
published by Nevins and colleagues [23] (GEO accession
GSE3151) to demonstrate SplicerAV’s ability to detect
oncogene driven changes in alternative processing. In
this experiment, activated HRAS, SRC, E2F3, activated
b-catenin (CTNNB1), MYC, or green fluorescent protein
(GFP) was over-expressed in human primary mammary
epithelial cells. The Affymetrix U133 plus 2.0 microarray
platform was used to assay gene expression in seven to
ten replicates of each condition. Probeset level intensi-
ties were estimated using the Robust Multichip Aver-
aging (RMA) procedure [34].
SplicerAV compared changes in probeset expression
between GFP and over-expression of the HRAS, SRC,
E2F3, CTNNB1, or MYC oncogenes (additional files 1,
2, 3, 4, and 5). Roughly 7,000 genes were expressed
above background in either GFP or oncogene over-
expression, depending on the oncogene ("Total” column;
Table 2). More than 2,000 of these genes were interro-
gated by multiple probesets, and could therefore be
examined by SplicerAV for evidence of changes in alter-
native mRNA processing ("Multi-probeset Genes” col-
umn). More than a hundred isoform specific changes
were predicted for each oncogene (Example SplicerAV
output shown in Figure 2A; “Alt. Processed Genes” col-
umn Table 2). HRAS over-expression caused 645 signifi-
cant isoform changes, suggesting HRAS-induced
changes in alternative processing in nearly a tenth of all
expressed genes. The median relative fold change
between isoforms was 1.39 (log2 fold change of .48),
with 61 (9%) of these genes predicted to undergo a
greater than two fold change in relative isoform abun-
dance (Figure 2B).
Gene isoform changes receiving both a significant p-
value and a positive splice score indicate ideal candi-
dates for further experimental study ("Genes with Splice
Score > 0” c o l u m n ;T a b l e2 ) .H R A Sa n dS R Co v e r -
expression resulted in 212a n d1 1 9s u c he v e n t s ,w h i l e
MYC over-expression resulted in only 12 (Table 2). One
gene, Programmed Cell Death Protein 5 (PDCD5),
underwent the same change in alternative processing
upon over-expression of each of the five oncogenes (see
additional files 1, 2, 3, 4, and 5). PDCD5 switched from
an alternative isoform (mRNA AK293486) to the major
isoform (mRNA BC015519), which codes 37 isoform
specific c-terminal amino acids required for PDCD5
nuclear entry & activation of apoptosis [35]. Gene ontol-
ogy (GO) analysis of isoform specific changes revealed a
common selection for genes involved in mRNA splicing
(see methods). Over-expression of all oncogenes other
Robinson et al. BMC Bioinformatics 2010, 11:108
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Page 5 of 16Table 2 SplicerAV predicts oncogene-induced changes in isoform specific mRNA levels
Unique Expressed Genes SplicerAV Predictions (P < .01)
GFP vs. Total Multi-probeset Genes Alt. Processed Genes Genes with Splice Score > 0 Significant Gene Ontologies
HRAS 7227 2185 645 212 mRNA splicing (12)
Complement med immunity (3)
G-protein mediated signaling (10)
SRC 7007 2015 291 119 Transcription Elongation (2)
mRNA splicing (7)
CTNNB1 7023 2019 159 54 mRNA processing factors (4)
E2F3 7313 2139 187 45 Cell surface receptor signal (10)
G-protein mediated signaling (6)
Mesoderm development (6)
Cell structure and motility (11)
pre-mRNA splicing (5)
Granulocyte-mediate immunity (2)
MYC 7081 2040 115 12 —
The total number of unique genes expressed above background, targeted by multiple probesets, predicted to undergo changes in alternative processing, or
those predicted to undergo ideal changes are shown in their respective columns for each oncogene (see text). Significantly enriched (p ≤ .05) biological
processes or molecular functions of these genes are shown in order of decreasing significance. The number of genes in each GO category is shown in
parentheses.
Figure 2 HRAS over-expression results in substantial relative isoform changes. (A) Example SplicerAV output comparing HRAS to GFP over-
expression. Genes are ranked in order of descending Splice Score (top three genes shown), with EGFR receiving the top score in HRAS over-
expression. Log2 fold change in expression and corresponding p-values from two tailed homoskedastic t-test of differential expression are shown
for individual probesets targeting each gene. Probesets are placed into A and B groupings by SplicerAV (see text). Splice score, SplicerAV p-value,
and two way ANOVA p-values are shown for each gene. (B) Distribution of the 645 isoform changes (AS Events) predicted by SplicerAV (p < .01)
upon HRAS over-expression in human primary mammary epithelial cells. For each gene, SplicerAV separates probesets into two similarly
behaving groups based on similar fold changes in expression. The average change in expression between probesets in these two groups
(AvgChange, see Equation 8 in methods) reflects the relative fold change in isoform abundance predicted by SplicerAV. Absolute relative fold
change in isoform abundance is shown in log base 2.
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ment of isoform specific changes in mRNA splicing,
pre-mRNA splicing, or mRNA processing factors (Table
2). HRAS and SRC over-expression resulted in predicted
isoform changes in 12 (p = .009) and seven (p = .05)
factors involved in mRNA splicing, respectively. Both
HRAS and E2F3 isoform specific changes were enriched
for G-protein mediated signaling (p = .04; p = .0009)
and roles in immune function (p = .02; p = .01). Sixty-
seven genes were predicted to undergo isoform changes
in common between two or more oncogenes. Messenger
RNA processing factors (5 genes, p = .008; WDR33,
HNRPC, SF3A1, SNRPA1, TRA2A) and mRNA splicing
factors (8 genes, p = .0003; HNRPC, HNRPD, TARDBP,
H N R P H 1 ,S F 3 A 1 ,H N R P A 2 B 1 ,S N R P A 1 ,T R A 2 A )w e r e
the most significant molecular function and biological
process represented by these genes.
HRAS over-expression results in isoform specific EGFR
mRNA regulation
Epidermal growth factor receptor (EGFR)w a st h et o p
ranked gene prediction in HRAS over-expression (p <
10
-5; additional file 1: Tab delimited SplicerAV output
of HRAS vs. GFP over-expression). EGFR expression
was interrogated by seven probesets, providing an ideal
opportunity to examine the behavior of multiple probe-
sets targeting different regions of the same gene.
Depending on the EGFR region being interrogated, pro-
besets reported either a significant increase or decrease
in expression upon HRAS over-expression (Figure 3).
Four main mRNA isoforms of EGFR are annotated in
the NCBI database, labeled A, B, C, and D. Isoform A
encodes the full length membrane bound tyrosine kinase
receptor [36,37]. Variants of isoform A have been
observed with either long (ALong)o rs h o r t( A Short)
3’UTRs (UCSC mRNA accession X00588[36] and
AK225422 [38]). Isoforms B and D encode truncated
intracellular domains (RefSeq NM_201282; RefSeq
NM_201284) and isoform C (RefSeq NM_201283)
encodes an EGFR v a r i a n tt h a tl a c k sat r a n s - m e m b r a n e
domain and is expected to be soluble [39].
Probesets 1 and 2, which target a region common to all
four isoforms, reported highly concordant (R
2 =. 9 5 )
expression levels across all 55 samples in the dataset (Fig-
ure 3C). Probesets targeting different transcript regions
(1 and 3) reported poor or even inversely correlated
expression levels, (R
2 = .36, Figure 3D). Due to this “out-
lier” behavior these probesets would be discarded during
conventional microarray expression analysis [40], how-
ever, SplicerAV data suggest that this behavior reflects
isoform-specific regulation of EGFR expression
EGFR isoform A (AShort) appeared to be the primary
transcript upregulated by HRAS over-expression, as evi-
denced by highly correlated expression of the probesets
targeting the common and AShort isoforms (probesets 1
and 6; R
2 = .87). HRAS over-expression caused a robust
decrease in the probeset targeting the long 3’UTR of
EGFR (probeset 7; ALong)t h a tw a sn o tc o r r e l a t e dw i t h
expression of the common transcript region (Figure 3F,
R
2 = .01). In contrast, common and ALong expression
levels were well correlated in non-HRAS samples (R
2 =
.70). These data suggest a HRAS-specific shortening of
the isoform A 3’UTR.
We hypothesize that these HRAS-induced isoform
changes promoted EGFR activation via several mechan-
isms. HRAS increased overall isoform A transcript
levels, as evidenced by significant increases in probesets
interrogating common regions of the gene (probesets 1
& 2). At the same time, HRAS over-expression resulted
in selection of a shorter 3’ UTR, which removes known
miRNA binding sites present in the ALong UTR and
likely increased translation of EGFR mRNAs [41]. Wide-
spread 3’UTR shortening to escape miRNA regulation
has been observed previously in proliferating cells [42].
EGFR isoforms B & D code for a truncated intracellular
domain, which if translated could dimerize with and
inhibit activation of both EGFR and HER2 [37]. The
observed down-regulation of these isoforms is predicted
to promote EGFR1 and HER2 activation [37]. It should
be noted, however, that the corresponding truncated
receptors have not been observed. Soluble isoforms
composed of the extracellular domain occur naturally
and suppress ligand-dependent EGFR signaling and
oncogenic transformation in a dominant negative man-
ner [43]. Our data indirectly address expression levels of
the soluble isoforms, which appear to be unchanged.
Our data suggest that HRAS acts through several iso-
form-specific mechanisms to promote EGFR family sig-
naling. EGFR signaling plays known roles in cell
survival, proliferation, adhesion, migration, and differen-
tiation [44]. Both EGFR and HER2 are currently thera-
peutic targets in breast cancer [45]. Our analysis here
suggests that modified regulation of alternative mRNA
processing could be used as a novel means of EGFR
inhibition, similar to that shown recently for HER2
using splice site switching oligonucleotides [46].
SplicerAV predicted isoform changes exhibit low overlap
with gene expression changes
Using the same gene expression dataset, SplicerAV was
able to predict a number of previously unappreciated
changes in isoform specific mRNA regulation. Genes
predicted to undergo isoform changes exhibited small
overlap with genes predicted to undergo expression
changes by conventional analysis, consistent with pre-
vious findings in the field [1,47,48]. HRAS and SRC
over-expression resulted in the largest changes in both
gene expression and isoform changes. Of the212 genes
Robinson et al. BMC Bioinformatics 2010, 11:108
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Page 7 of 16predicted to undergo ideal isoform changes (significant
p-value and positive splice score) in HRAS over-expres-
sion, only 8 genes (3.8%) were also among the top 212
most significant changes by conventional expression
analysis (data not shown). Of the top 119 predicted iso-
form changes in SRC over-expression, none were in the
top 119 most significant expression changes. This low
degree of overlap suggests that the results obtained via
SplicerAV are largely orthogonal to that of conventional
gene expression analyses. This low degree of overlap
provides the potential for combining traditional gene
expression signatures with SplicerAV isoform-based sig-
natures to improve signature performance.
SplicerAV predicts isoform changes in high vs. low grade
breast tumors
Our analysis of oncogene regulated isoform expression
demonstrated the ability to generate novel insights into
cancer biology. We next determined if similar insights
could be obtained from the analysis of alternative pro-
cessing in clinical tumor samples. Breast cancer has
been extensively studied using high-throughput analyses
of gene expression at the transcriptome level (Reviewed
in [49]). In contrast, high-throughput analysis of alterna-
tive mRNA processing in breast cancer has been
addressed in only a handful of studies [12,47]. We
explored the ability of SplicerAV to detect changes in
Figure 3 HRAS over-expression causes isoform specific regulation of Epidermal Growth Factor Receptor (EGFR) in human mammary
epithelial cells. (A) Probesets on the Affymetrix U133 2.0 plus array interrogate EGFR expression at seven different genomic locations. Up and
down arrows indicate each probeset’s expression changes in HRAS over-expression compared to GFP controls. Probeset 5 experienced a
significant decrease in expression with HRAS over-expression, but was not expressed above background. B) UCSC genomic alignment of
probesets and EGFR isoforms. Four previously observed EGFR isoforms (A, B, C and D) are shown with exons represented as black boxes and
introns as hashed lines. Extracellular, transmembrane, and intracellular domain regions are shown below the alignment. C-F) Scatter plots of
logged expression levels of all 55 samples (GFP, MYC, SRC, CTNNB1, E2F3, and HRAS) for selected pairs of probesets C) Probesets 1 and 2 target
a transcript region common to all major isoforms and exhibit highly correlated expression (R2 = .95). D) Probesets 1 and 3 target the common
region vs. isoform B specific region and demonstrate a weak inverse relationship (R2 = .36). E) Probesets 1 and 6 interrogate the common vs.
AShort isoform region, demonstrating a high degree of correlation across all samples (R2 = .87). F) In contrast, probesets 1 and 7 interrogate
common and ALong isoform region and are not correlated (R2 = .01) due to the HRAS induced 3’UTR shortening of EGFR A transcripts.
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Page 8 of 16alternative processing between low and high grade
breast tumors in archival expression data.
Sotiriou and colleagues profiled 87 Tamoxifen treated,
estrogen receptor (ER) positive tumors obtained from
Guys Hospital, London (GUYT) using the Affymetrix
HG-U133 PLUS2 Genechip™[50] (GEO accession
GSE6532, RMA normalized). Using this dataset, we
examined changes in probeset expression between low
grade (I, n = 17) and high grade (III, n = 16) breast
tumors. Analysis was limited to probesets present on
either the U133A or U133B arrays in order to validate
changes in two independent data sets discussed in the
next section. 11,248 unique genes were expressed above
background in either the low or high grade tumor sam-
ples. Among the 4,031 genes interrogated by multiple
probesets, SplicerAV predicted that 974 genes under-
went significant isoform changes between aggressive
a n dn o n - a g g r e s s i v eb r e a s tt u m o r s( p<. 0 1 ;s e ea d d i -
tional file 6: Tab delimited SplicerAV output of Grade I
vs. Grade III human breast tumors). Removing genes
with negative splice scores yielded a refined list of 241
genes. GO analyses of these 241 genes revealed signifi-
cant (p < .05) enrichment for several molecular func-
tions including guanyl-nucleotide exchange factors
(RAB3IP, RAPGEF2, GAPVD1, CD47, TRIO, ARHGEF7,
AKAP13; p = .006), metalloprotease inhibitors (TIMP2,
TIMP3; p = .007), ubiquitin-protein ligases (RNF130,
TTC3 UBE3B, PML, TRIM26, RBCK1, MIB1, ZNF294,
ZUBR1, TRIAD3; p = .007), and mRNA processing fac-
tors (SYNCRIP, WDR33, SFRS8, SFRS15, TAF15, SF1,
SF3B1, SFPQ, PRP6; p = .01; Table 3).
SplicerAV predicted isoform changes are associated with
breast cancer survival
SplicerAV probeset groupings of genes identified in the
GUYT training set were used to create individual sam-
ple level indexes of relative isoform abundance. We
tested an association of these SplicerAV indexes in two
independent validation datasets to examine whether
specific isoform changes observed in high grade tumors
were also associated with poor patient prognosis (see
methods). Previous datasets generated by Miller [51]
(GSE3494) and Pawitan [52] (GSE1456) have indepen-
dently profiled breast tumor gene expression using the
Affymetrix U133 A and B microarrays (probeset intensi-
ties were estimated using MAS5 [53]). These studies
include patient outcome, providing the opportunity to
test for an association of isoform changes with survival
in ER positive tumors.
We generated 687 SplicerAV Indexes from the 241
genes identified in the GUYT training set and calculated
their value for each tumor sample in the validation sets.
For each SplicerAV Index, tumors were sorted into the
top and bottom 50
th percentile of tumors. High and low
SplicerAV Index groups were then tested for a differ-
ence in survival. The GUYT training set had previously
determined whether a SplicerAV index was predicted to
be increased or decreased in aggressive cancer (defined
as Grade III vs Grade I). This pre-specified association
with aggressive cancer was used to conduct one-sided
logrank tests (p < .05) for an association with breast
cancer survival for each SplicerAV index in the valida-
tion datasets. Failure in the Miller dataset was defined
as death from any cause and failure in the Pawitan data-
set was defined as death from breast cancer (inherent to
the clinical data available). Of the 241 genes tested, 15
genes possessed indexes that were significantly asso-
ciated with survival in both datasets (Table 4). Guanyl-
nucleotide exchange factors (GEFs) and mRNA proces-
sing factors were both enriched among the original 241
genes tested. Interestingly, these GO categories were
both represented among the 15 validated genes includ-
ing ARHGEF7, a guanyl-nucleotide exchange factor, and
SFPQ, an mRNA processing factor.
Few studies have performed high-throughput exami-
nation of alternative processing in clinical tumor sam-
ples [12,13] and to our knowledge no prior studies have
examined changes in alternative mRNA processing
Table 3 GO analysis of 241 genes predicted to undergo isoform changes between grade I and grade III breast tumors
(GUYT)
Molecular Function # Genes P-Value Gene Symbols
Guanyl-nucleotide exchange factor 7 6.22E-03 RAB3IP, RAPGEF2, GAPVD1, CD47, TRIO, ARHGEF7, AKAP13
Metalloprotease inhibitor 2 6.52E-03 TIMP2, TIMP3
Ubiquitin-protein ligase 10 7.40E-03 RNF130, TTC3 UBE3B, PML, TRIM26, RBCK1, MIB1, ZNF294, ZUBR1, TRIAD3
mRNA processing factor 9 1.27E-02 SYNCRIP, WDR33, SFRS8, SFRS15, TAF15, SF1, SF3B1, SFPQ, PRP6
Cytoskeletal protein 4 3.42E-02 DNAL1, NF2, KIF5C, DYNC1H1
Anion channel 2 3.63E-02 PML, CLCN3
G-protein modulator 12 4.64E-02 RAB3IP, RAPGEF2, GAPVD1, CD47,
mRNA splicing factor 6 4.94E-02 TAF15, SFRS8, SF1, SF3B1, SFPQ, PRP6
Tyrosine protein kinase receptor 4 4.97E-02 TEK, TPR, IGF1R, PDGFRA
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Page 9 of 16directly associated with cancer patient survival. This
study examined isoform specific mRNA levels in over
400 human clinical samples, providing support for the
use of changes in alternative processing as potential
prognostic markers in cancer.
ARHGEF7 &EIF4E2 isoform changes are associated with
breast cancer survival
A SplicerAV index for Rho guanine nucleotide exchange
factor 7 (ARHGEF7) was decreased in high vs. low grade
tumors within the GUYT dataset, and was significantly
associated with survival in both the Miller (p = .008)
and Pawitan (p = .009) datasets. ARHGEF7 expression
was assayed by three annotated probesets, providing an
opportunity to compare associations of survival with
either SplicerAV index or individual probeset expres-
sion. The SplicerAV index for ARHGEF7 compared the
ratio of a decreasing ("Down”) probeset located in the
3’UTR of ARHGEF7 to that of two increasing ("Up1”
and “Up2”) probesets located in shorter transcripts
( F i g u r e4 A ) .W ec o m p a r e dt h eARHGEF7 SplicerAV
index and each individual probeset for an association
with breast cancer survival and noted that the SplicerAV
index outperformed individual probeset in both datasets
(Figure 4B).
A SplicerAV index for Eukaryotic translation initiation
factor 4E family member 2 (EIF4E2) was increased in
Table 4 Isoform changes in gene expression significantly
associated with patient outcomes in both validation
datasets
SplicerAV Predictions Association with
Survival
Gene Symbol† Isoform Probeset Hypothesis Miller Pawitan
ARHGEF7 202548_s_at DOWN *0.009 *0.008
DPP7 241973_x_at DOWN *0.001 *0.007
EIF4E2 209393_s_at UP **0.002 *0.003
MAPKAP1 222426_at DOWN *0.019 *0.003
SLC28A10 230448_at UP *0.007 0.032
PDXK 202671_s_at UP **0.001 0.025
POLI 238992_at UP 0.037 0.052
SFPQ 201585_s_at UP 0.062 0.041
SIVA1 203489_at UP *0.005 0.075
SSU72 223051_at UP *0.018 *0.007
TFDP2 203588_s_at UP 0.054 *0.008
TIMP2 231579_s_at DOWN **0.001 0.056
TncRNA 234989_at UP **0.001 0.034
WDFY3 212606_at UP 0.049 *0.010
WDR26 224897_at UP **0.001 0.049
†For genes possessing multiple significant SplicerAV Indices, only one isoform
is shown.
*Significant association with survival (p < .01), one sided log rank test
** Significant association with survival (p < .001), one sided log rank test
Figure 4 SplicerAV Index of ARHGEF7 is associated with breast cancer survival. Panel A. Schematic representation of ARHGEF7 isoforms A,
B and C, with regions interrogated by probesets that increase shown as Probesets Up 1 and 2 (red arrows), and the region which decreases
denoted as Probeset Down (blue arrow). Panel B. The fraction of patients surviving in each cohort (vertical axis) is shown over time in years
(horizontal axis) as a function of individual probeset expression or SplicerAV index. Survival of patients in the top (red line) and bottom (blue
line) 50th percentile are plotted by individual probeset expression (Down, UP1, and UP2) and the SplicerAV index within the Miller (left) and
Pawitan (right) cohorts. Results of two-tailed logrank tests of survival are shown, with asterisks indicating significance at the .05 (large asterisk)
and .10 (small asterisk) levels.
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Page 10 of 16high vs. low grade tumors within the GUYT dataset, and
was significantly associated with survival in both the
Miller (p = .002) and Pawitan (p = .003) datasets. The
SplicerAV index for EIF4E2 compared the ratio of an
increasing “Up” probeset targeting a coding region to
that of a decreasing “Down” probeset located in the
3’UTR of the longest transcript (Figure 5A). For EIF4E2,
survival could be predicted by an increase in the “Up”
probeset alone (Miller, p = .003; Pawitan, p = .0007;
Figure 5B). Low levels of the “Down” probeset were
only significantly associated with poor survival in the
Pawitan cohort (p = .04).
Whether or not individual probesets could demon-
strate a consistent association with survival differed by
gene. Although individual probeset behavior may repre-
sent an alternative processing event, only through com-
parison with other probesets for that gene can
SplicerAV uncover these relevant and predictive iso-
forms that would go unnoticed in conventional analyses.
Combining isoform changes from multiple genes
improves prediction of breast cancer survival
We chose a subset of the 15 validated isoform changes
to examine the potential for generating an isoform sig-
nature that combined information from multiple iso-
form changes to improve prognostic accuracy. We
initially chose the six genes, EIF4E2, ARHGEF7,
SLC28A10, PDXK, TncRNA,a n dMAPKAP1,t h a tp r o -
duced the clearest separation between good and poor
survival in individual prognostic analyses (data not
shown). Stratifying patients by SplicerAV index for each
gene demonstrated the expected association with survi-
val (Figure 6A-F). The number of poor prognostic
events was tallied for each patient. Survival was then
plotted for individuals with low (0-1 events, blue), inter-
mediate (2-4 events, black), or high (5-6 events, red)
numbers of poor prognostic events (Figure 6G). This
stratification of patients by total poor prognostic events
demonstrated highly significant associations with survi-
val in both the Miller (p = 6e-7) and Pawitan (p = 4e-7)
cohorts. The combined isoform signature demonstrated
prognostic value beyond that of any individual isoform
or probeset change.
Similar to our in vitro analyses of oncogene over-
expression, we observed low overlap between gene
expression and SplicerAV changes. Of the 241 isoform
changes predicted by SplicerAV in the GUYT training
set that were later tested for an association with poor
prognosis, only one gene (0.4%), BTD, was also among
t h et o p2 4 1d i f f e r e n t i a l l ye x p r e s s e dg e n e s .T h eo r t h o -
gonality of candidate gene lists identified by SplicerAV
and conventional methods suggests that these two
Figure 5 EIF4E2 probesets are associated with breast cancer survival. Panel A. Schematic representation of EIF4E2 isoforms A and B, with
region interrogated by probesets shown as Up (red arrow), and Down (blue arrow). For panels B, C, and D, the fraction of patients surviving in
each cohort (vertical axis) is shown over time in years (horizontal axis) as a function of individual probeset expression or SplicerAV index. Survival
of patients in the top (red line) and bottom (blue line) 50th percentile are plotted by individual probeset expression (B, C) and the SplicerAV
index (D) within the Miller (left) and Pawitan (right) cohorts. Results of two-tailed logrank tests of survival are shown, with asterisks indicating
significance at the .05 level.
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provide independent value in generating molecular clas-
sifiers. SplicerAV can generate both conventional and
isoform specific gene expression analyses, and therefore
provides two non-redundant datasets from one
experiment.
General Discussion
Traditional analyses of genee x p r e s s i o nd a t ah a v ec o n -
sidered the probeset as the basic unit of expression.
Under this paradigm, the presence of multiple probesets
has been viewed largely as a nuisance. Current
approaches dealing with the issue of multiple probesets
have used either probeset location or the mean, median,
or largest probeset expression change to distill multiple
probesets into a single gene level expression value. Each
of these approaches would have yielded a different read-
out of EGFR expression changes in HRAS over-
expression, making conventional interpretation inade-
quate for such genes. Software has even been developed
whose sole purpose is the removal of discordant probe-
set expression values for probesets targeting the same
gene [40].
We propose that for genes with multiple probesets,
isoform specific expression changes may be a more
appropriate means of interpreting standard microarray
expression data than the current one gene = one probe-
set paradigm. Previous algorithms [54,55] have exam-
ined the possibility of investigating changes in
alternative processing using single probeset level data.
These methods have relied on custom chips, or would
not have detected events predicted by SplicerAV in this
paper because such methods do not examine events
spanning multiple probesets. SplicerAV provides a sys-
tematic means by which to detect and interpret incon-
sistent probeset behavior within the same gene, a
Figure 6 A six isoform signature provides improved prediction of breast cancer survival compared to individual isoforms. The fraction
of patients surviving in each cohort (vertical axis) is shown over time in years (horizontal axis) as a function of individual probeset expression or
SplicerAV index. Survival of patients in the top (red line) and bottom (blue line) 50th percentile are plotted by the SplicerAV index for six genes;
EIF4E2 (A), ARHGEF7 (B), SLC28A10 (C), PDXK (D), TncRNA (E), MAPKAP1 (F) for the Miller (left) and Pawitan (right) cohorts. Patients survival
stratified by a low (0-1), intermediate (2-4), and high (5-6) number of poor prognostic events is shown in panel G.
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Page 12 of 16situation where an oversimplified perspective may be
obscuring relevant and important biological changes.
This study marks the first en masse analysis of mRNA
isoform changes in existing conventional expression
microarray data. We have shown here that re-analyzing
such data using a different paradigm can uncover novel
biological insights and potential prognostic markers.
Conclusion
The combination of material, personnel, and clinical
costs of obtaining gene expression microarray data has
resulted in a massive archive of these data accumulated
over the past two decades. Many previously created data-
sets, particularly clinical datasets, are unique and cannot
be reproduced. Numerous private and public repositories
of microarray expression data exist, with the largest pub-
lic repository, Gene Expression Omnibus, containing
over 50,000 data samples from the Affymetrix U133 and
U95 series alone. In this paper we demonstrate the utility
of SpicerAV, the first program used to analyze this exist-
ing data en masse for isoform specific changes that can
result from alternative mRNA processing.
Methods
SplicerAV algorithm details
SplicerAV takes probeset intensities generated using
conventional normalization methods (i.e. MAS5 or
RMA output) as input. SplicerAV first summarizes the
average log2fold change in expression and the corre-
sponding t-statistic for each probeset on the array. Pro-
beset changes are assigned an initial weight based on
their normalized t-statistic, TNorm. Conceptually, weight-
ing by TNorm counts probesets undergoing significant
expression changes one time. This is because TNorm
equals one for probesets reporting expression changes
significant at the .05 level (two tailed t-test).
T Treatment Control
Treatment Control
T Norm Critical =
−
÷
|| 
 22 (3)
Probesets targeting the same gene are next grouped
together using annotation provided by the array manu-
facturer. Genes targeted by probesets with a TNorm value
greater than one scale their weights so that the maxi-
mum TNorm within that gene is reduced to one. This
prevents counting any probeset more than once.
If Max T then Weight
TNorm
Max TNorm
Norm ()
()
>= 1 (4)
Else Weight TNorm =
At this step, individual probeset weights are raised to
a user specified power (Wt_scale, default = 2), which
allows preferential focus on more significant probeset
changes in expression at the cost of removing informa-
tion from less reliable probesets and reducing the power
of significance tests.
This weighting scheme assigns a weight between 0
and 1 to each probset, indicating the number of times a
probeset’s observations will be counted in the Gaussian
mixture model. In the final Gaussian mixture model,
each probeset weight is multiplied by the average num-
ber of paired observations among treatment and control
groups for that probeset (Navg_obs =( N treat_obs +N contro-
l_obs)/2). The resulting model counts each effective pair
of observations for a probeset at most once, with less
reliable probesets being counted less.
Effective Weight
EfWt
Weight Av
prbset
prbset
prbset
Wt Scale
=
= () *
_ g gO b s prbset _
(5)
The Effective Weight for each probeset is used as the
final probeset summary weight in the Gaussian mixture
model. Average probeset log2fold changes in expression
are fitted using two models, which contain one and two
Gaussian distributions, respectively. Comparison of the
relative fit under these two models yields a maximum
likelihood ratio (MLR), which can be assessed for statis-
tical signifance using a standard likelihood ratio (LR)
test statistic, asymptotically distributed as c
2(2), for each
gene.
MLR
LikelihoodA
IfA LikelihoodB
IfB
LikelihoodSingle prbset
=
=
* * *
1 1
Tot prbsets _
∏ (6)
Where:
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i
Xprbset i
i
i
Ef
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⎜
⎞
⎠
⎟
⎟
⎡
⎣
⎢
⎢
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⎤
⎦
⎥
⎥
⎥
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

exp
()
W Wtprbset
Xprbset = the log2fold expression change of that
probeset
μA = the weighted average log2fold change in
expression for probesets assigned to groupA
μB = the weighted average log2fold change in
expression for probesets assigned to groupB
μSingle = the weighted average log2fold change in
expression for all probesets targeting the gene
sA, sB,a n dssingle f o rg r o u p sA ,B ,a n da l lp r o b e s e t s
are determined by expectation maximization, bounded
b yam i n i m u mv a l u eo f1 0 %t op r e v e n to v e r - f i t t i n gb y
the model. The value of 10% was chosen as a
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summarized significant log2fold probeset changes, which
consistently exhibited standard deviations (s) below 10%
across analyzed datasets (data not shown).
Biological Modifiers
SplicerAV incorporates biologically motivated modifiers
to alter the relative ranking of potential changes in alter-
native processing to suit the final objectives of the user.
These modifiers can be adjusted by the user and do not
affect the p-values reported by SplicerAV. The specified
form and magnitude of these biologically motivated
modifiers were empirically derived through analysis of
several datasets.
Multiple Probeset Modifier
The multiprobeset modifier adjusts the splice score by
the total possible ways that all the probesets targeting a
given gene can be placed into groups of two. This
method penalizes genes containing large numbers of
probesets capable of generating a large number of alter-
native processing hypotheses which are difficult to inter-
pret, using a bonferroni multiple hypothesis correction.
Multiprobeset Modifier
tot prbsets =− −
− ln( )
_ 21
1 (7)
Expression Cutoff Modifier
The expression cutoff modifier calculates the log2 differ-
ence in average expression between the two groups of
probesets, A and B. Genes whose expression between
groups falls below a user specified threshold minimum
fold change are penalized using a smoothed function
whose steepness is set using a user specified sharpness
parameter.
If AvgChange Cutoff
Cutoff Modifier Sharpness AvChange Cu
<
=
,
*ln( / t toff) (8)
Centering Modifier
The centering modifier preferentially ranks genes whose
probeset expression changes in opposite directions, sug-
gesting a qualitatively different event which cannot be
explained by poor annotation of probesets targeting
intronic regions, saturated probeset signals, non-hybri-
dizing probesets, or other probeset expression behavior
deviating from a linear relationship with transcript
abundance. Genes in which both groups of probesets
change in the same direction (either both increasing or
decreasing) are penalized, while genes containing groups
of probesets with mean expression levels moving in
opposite directions are given a bonus.
If Mean Mean Exp
then Centering Factor Centerin
GrpA GrpB (* ) , ΔΔ <
=−
0
g gF a c t o r
Centering Modifier
Centering Factor Min Mean GrpA = *( | | , Δ | || ) Mean ExpGrpB Δ
(9)
Gene Ontology Analyses
Gene ontology (GO) analyses compared genes with Spli-
cerAV predicted isoform changes (p < .01, splice score >
0) to a reference set of all genes evaluated for isoform
changes in each condition using PANTHER [56,57].
Non-overlapping GO categories with more than one
gene were reported.
Additional file 1: Tab delimited SplicerAV output of HRAS vs. GFP over-
expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
108-S1.TXT]
Additional file 2: Tab delimited SplicerAV output of SRC vs. GFP over-
expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
108-S2.TXT]
Additional file 3: Tab delimited SplicerAV output of E2F3 vs. GFP over-
expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
108-S3.TXT]
Additional file 4: Tab delimited SplicerAV output of CTNNB1 vs. GFP
over-expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
108-S4.TXT]
Additional file 5: Tab delimited SplicerAV output of MYC vs. GFP over-
expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
108-S5.TXT]
Additional file 6: Tab delimited SplicerAV output of Grade I vs. Grade III
human breast tumors (GUYT).
Click here for file
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108-S6.TXT]
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